Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02735707
Registration number
NCT02735707
Ethics application status
Date submitted
11/12/2015
Date registered
13/04/2016
Date last updated
28/02/2024
Titles & IDs
Public title
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Query!
Scientific title
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Query!
Secondary ID [1]
0
0
2015-002340-14
Query!
Secondary ID [2]
0
0
U1111-1189-1653
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
REMAP-CAP
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Community-acquired Pneumonia, Influenza, COVID-19
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ceftriaxone
Treatment: Drugs - Moxifloxacin or Levofloxacin
Treatment: Drugs - Piperacillin-tazobactam
Treatment: Drugs - Ceftaroline
Treatment: Drugs - Amoxicillin-clavulanate
Treatment: Drugs - Standard course macrolide
Treatment: Drugs - Extended course macrolide
Other interventions - No systemic corticosteroid
Treatment: Drugs - Fixed-duration Hydrocortisone
Treatment: Drugs - Shock-dependent hydrocortisone
Treatment: Drugs - Fixed-duration higher dose Hydrocortisone
Other interventions - No antiviral agent for influenza
Treatment: Drugs - Five-days oseltamivir
Treatment: Drugs - Ten-days oseltamivir
Other interventions - No antiviral agent for COVID-19
Treatment: Drugs - Lopinavir / Ritonavir
Treatment: Drugs - Hydroxychloroquine
Treatment: Drugs - Hydroxychloroquine + lopinavir/ritonavir
Treatment: Drugs - Ivermectin
Other interventions - No immune modulation for COVID-19
Treatment: Drugs - Interferon beta-1a
Treatment: Drugs - Anakinra
Treatment: Drugs - Tocilizumab
Treatment: Drugs - Sarilumab
Treatment: Drugs - Local standard venous thromboprophylaxis
Treatment: Drugs - Therapeutic dose anticoagulation
Treatment: Drugs - Conventional low dose thromboprophylaxis
Treatment: Drugs - Intermediate dose thromboprophylaxis
Treatment: Drugs - Continuation of therapeutic dose anticoagulation
Other interventions - No immunoglobulin
Other interventions - Convalescent plasma
Other interventions - Delayed administration of convalescent plasma
Other interventions - No vitamin C
Treatment: Drugs - Vitamin C
Other interventions - No antiplatelet
Treatment: Drugs - Aspirin
Treatment: Drugs - P2Y12 inhibitor
Other interventions - No simvastatin
Treatment: Drugs - Simvastatin
Other interventions - Placebo
Treatment: Drugs - Eritoran
Treatment: Drugs - Apremilast
Treatment: Surgery - Clinician-preferred mechanical ventilation strategy
Treatment: Surgery - Protocolised mechanical ventilation strategy
Other interventions - No renin-angiotensin system inhibitor
Treatment: Drugs - Angiotensin converting enzyme inhibitor
Treatment: Drugs - Angiotensin Receptor Blockers
Treatment: Drugs - ARB + DMX-200
Other interventions - No cysteamine
Treatment: Drugs - Cysteamine
Treatment: Drugs - Fixed-duration dexamethasone
Treatment: Drugs - Baloxavir Marboxil
Treatment: Drugs - Five-days oseltamivir + baloxavir marboxil
Treatment: Drugs - Ten-days oseltamivir + baloxavir marboxil
Other interventions - No endothelial modulator
Treatment: Drugs - Imatinib
Other interventions - No Immune Modulator for Influenza
Treatment: Drugs - Tocilizumab
Treatment: Drugs - Baricitinib
Other interventions - No antiviral agent for COVID-19
Treatment: Drugs - Nirmatrelvir/ritonavir
Treatment: Drugs - Remdesivir
Treatment: Drugs - Nirmatrelvir/ritonavir + remdesivir
Other: Antibiotic Domain - Patients with community-acquired pneumonia admitted to participating intensive care units and requiring empiric antibiotic therapy will be randomised one of five antibiotic interventions.
Note: the ceftaroline + macrolide intervention has been closed to recruitment.
Other: Macrolide Duration Domain - Patients with community-acquired pneumonia admitted to participating intensive care units who have been allocated to a beta-lactam antibiotic intervention in the Antibiotic Domain will be randomised to either a standard course or extended course of macrolide therapy
Other: Corticosteroid Domain - Patients with community acquired pneumonia (CAP) admitted to participating hospitals will be randomised to a steroid use strategy.
Note: this domain is now closed to patients with suspected or proven COVID-19. It remains open to patients with CAP without COVID-19.
Other: Influenza Antiviral Domain - Patients with community-acquired pneumonia admitted to participating hospitals with microbiological testing confirmed influenza infection will be randomised to one of six interventions.
Other: COVID-19 Antiviral Domain - Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to no ivermectin or ivermectin.
Note: an earlier version of this domain evaluated lopinavir-ritonavir, hydroxychloroquine, and combination lopinavir-ritonavir and hydroxychloroquine against a 'no antiviral' control.
This domain is now closed.
Other: COVID-19 Immune Modulation Domain - Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five interventions.
Note: this domain is now closed.
Other: Anticoagulation Domain - Patients admitted to participating intensive care units with suspected or microbiological testing confirmed COVID-19 will be randomised to an anticoagulation strategy.
Note: A previous version of this domain evaluated local standard venous thromboprophylaxis against therapeutic dose anticoagulation. This domain is now closed.
Other: Immunoglobulin Domain - Immunosuppressed patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive no immunoglobulin for COVID-19, or to receive high-titre convalescent plasma.
Note: an earlier version of this domain was not restricted to immunosuppressed patients.
Other: Vitamin C Domain - Patients admitted to participating hospitals with community-acquired pneumonia will be randomised to receive no vitamin C, or vitamin C.
Note: this domain is now closed.
Other: Simvastatin Domain - Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no simvastatin, or simvastatin.
Note: this domain is now closed.
Other: Antiplatelet Domain - Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to receive no antiplatelet, aspirin, or site-preferred P2Y12 inhibitor.
Note: this domain is now closed.
Other: Mechanical Ventilation Domain - Patients with community-acquired pneumonia admitted to participating intensive care units who are intubated and receiving invasive mechanical ventilation will be randomised to protocolised mechanical ventilation strategy, or clinician-preferred mechanical ventilation strategy
Other: COVID-19 Immune Modulation (2) Domain - Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to receive one of three interventions.
Note: this domain is now closed.
Other: ACE2 RAS Domain - Patients admitted to participating hospitals with suspected or microbiological testing confirmed COVID-19 will be randomised to one of up to five renin-angiotensin system blockade strategies.
Note: this domain is now closed.
Other: Cysteamine Domain - Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no cysteamine, or cysteamine.
Note: this domain is now closed.
Other: Endothelial Domain - Patients admitted to participating hospitals with severe community-acquired pneumonia, including patients with suspected or proven influenza or COVID-19, will be randomised to receive no endothelial modulator or enteral imatinib.
Other: Influenza Immune Modulation - Patients with community-acquired pneumonia admitted to participating intensive care units with microbiological testing confirmed influenza infection will be randomised to one of three interventions.
Other: COVID-19 Antiviral (II) Domain - Patients admitted to participating hospitals with microbiological testing confirmed COVID-19 will be randomised to one of up to four interventions.
Treatment: Drugs: Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Treatment: Drugs: Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Treatment: Drugs: Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Treatment: Drugs: Ceftaroline
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Treatment: Drugs: Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Treatment: Drugs: Standard course macrolide
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Treatment: Drugs: Extended course macrolide
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.
Other interventions: No systemic corticosteroid
Patients are not to receive any systemic corticosteroids, including hydrocortisone, to study day 28 or hospital discharge (whichever occurs first).
Treatment: Drugs: Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Treatment: Drugs: Shock-dependent hydrocortisone
50mg IV hydrocortisone every 6 hours while the patient is in septic shock
Treatment: Drugs: Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.
Note: this intervention was only available to patients with suspected or proven COVID-19 and is now closed.
Other interventions: No antiviral agent for influenza
No antiviral agent intended to be active against influenza infection is to be administered
Treatment: Drugs: Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)
Treatment: Drugs: Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)
Other interventions: No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Treatment: Drugs: Lopinavir / Ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Note: this intervention is now closed.
Treatment: Drugs: Hydroxychloroquine
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Treatment: Drugs: Hydroxychloroquine + lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).
Note: this intervention is now closed.
Treatment: Drugs: Ivermectin
Ivermectin administered enterally at a dose of 0.2 mg/kg once daily with a maximum daily dose of 24mg/day.
Other interventions: No immune modulation for COVID-19
No immune modulating agent intended to be active against COVID-19 is to be administered.
Note: this intervention is now closed.
Treatment: Drugs: Interferon beta-1a
IFN-ß1a 10 µg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-ß1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.
Note: this intervention is now closed.
Treatment: Drugs: Anakinra
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered every 6 hours.
In patients with renal impairment, anakinra will be administered on alternate days.
Note: this intervention is now closed.
Treatment: Drugs: Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.
Note: this intervention is now closed.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Treatment: Drugs: Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.
Note: this intervention is now closed.
Treatment: Drugs: Local standard venous thromboprophylaxis
Standard venous thromboprophylaxis that complies with local guidelines or usual practice will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Treatment: Drugs: Therapeutic dose anticoagulation
Patients will be administered either low molecular weight heparin (LMWH) or unfractionated heparin (UFH) to achieve systemic anticoagulation. Either agent may be used and the same patient may be switched between UFH and LMWH at the discretion of the treating clinician.
Note: this intervention is now closed.
Treatment: Drugs: Conventional low dose thromboprophylaxis
Low dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Treatment: Drugs: Intermediate dose thromboprophylaxis
Intermediate dose thromboprophylaxis will be administered for 14 days following randomisation or until hospital discharge, whichever occurs first. Dosing is outlined in the relevant protocol documents for this domain.
Treatment: Drugs: Continuation of therapeutic dose anticoagulation
Patients already receiving therapeutic dose anticoagulation at the time of randomisation to this intervention will be administered either unfractionated heparin by IV infusion or low-molecular weight heparin to achieve systemic anticoagulation according to local practice for acute VTE treatment for 14 days following randomisation or until hospital discharge, whichever occurs first.
Other interventions: No immunoglobulin
No immunoglobulin intended to be active against SARS-CoV-2 infection is to be administered.
Note: this intervention is now closed.
Other interventions: Convalescent plasma
Patients will receive at least one and no more than two units of ABO compatible convalescent plasma within 48 hours of randomisation.
Note: this intervention is now closed.
Other interventions: Delayed administration of convalescent plasma
Note: this intervention is now closed.
Other interventions: No vitamin C
No high dose intravenous vitamin C is to be administered
Treatment: Drugs: Vitamin C
Intravenous Vitamin C 50mg/kg administered every 6 hours for 16 doses
Other interventions: No antiplatelet
No antiplatelet agent or NSAID to be administered.
Note: this intervention is now closed.
Treatment: Drugs: Aspirin
Aspirin administered at either 75mg or 100mg once per day for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Treatment: Drugs: P2Y12 inhibitor
Site-selected P2Y12 inhibitor:
Clopidogrel: administered 75 mg once per day for 14 days or until hospital discharge, whichever occurs first.
Prasugrel: If patient is aged less than 75 years and measured or estimated weight if 60kg or more, and initial loading dose of prasugrel 60 mg will be administered, followed by maintenance dose of 10 mg per day.
Ticagrelor: administered enterally at 60mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Other interventions: No simvastatin
No simvastatin intended to be active against COVID-19 is to be administered
Treatment: Drugs: Simvastatin
Simvastatin 80mg administered once daily via enteral route, while the patient remains in hospital up to 28 days after randomisation
Other interventions: Placebo
Treatment: Drugs: Eritoran
Eritoran initiated with a 26.24 mg loading dose (6.56 mg/h IV for 4 hours), followed by a second 13.12 mg loading dose (6.56 mg/h IV for 2 hours) at 12 hours after initiation. Patients will then receive twenty-six 6.56 mg maintenance doses (3.28 mg/h IV for 2 hours) every 12 hours thereafter (total of 14 days). Dosing will be stopped if the patient is discharged from hospital
Treatment: Drugs: Apremilast
Apremilast administered 30mg twice daily for 14 days or until hospital discharge, whichever occurs first.
Note: this intervention is now closed.
Treatment: Surgery: Clinician-preferred mechanical ventilation strategy
Clinician-preferred ventilation strategy, including mode of ventilation and all ventilatory parameters
Treatment: Surgery: Protocolised mechanical ventilation strategy
Invasive mechanical ventilation strategy delivered as outlined in relevant protocol documents for this domain.
Other interventions: No renin-angiotensin system inhibitor
No RAS inhibitor (i.e. no ACEi or ARB) is to be administered up to the end of study day 10.
Treatment: Drugs: Angiotensin converting enzyme inhibitor
Site-preferred ACEi agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Treatment: Drugs: Angiotensin Receptor Blockers
Site-preferred ARB agent administered as directed by the treating clinician for 10 days or until hospital discharge, whichever occurs first.
Treatment: Drugs: ARB + DMX-200
Site-preferred ARB agent administered in combination with DMX-200 for 10 days or until hospital discharge, whichever occurs first.
ARB administered as directed by the treating clinician. DMX-200 administered enterally at a dose of 120mg twice daily.
Other interventions: No cysteamine
No cysteamine to be administered until the end of study day 10 or hospital discharge, whichever occurs first.
Treatment: Drugs: Cysteamine
Cysteamine administered every 8 hours at a dose of 5 mg/kg estimated or measured body weight (maximum dose of 500mg), for ten days or until ICU discharge, whichever occurs first.
Treatment: Drugs: Fixed-duration dexamethasone
6 mg of IV or enteral dexamethasone will be administered daily for up to 10 days while in hospital.
Treatment: Drugs: Baloxavir Marboxil
Baloxavir marboxil administered on days 1 and 4 post-randomisation.
Treatment: Drugs: Five-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Treatment: Drugs: Ten-days oseltamivir + baloxavir marboxil
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first), in addition to baloxavir marboxil administered on days 1 and 4 post-randomisation.
Other interventions: No endothelial modulator
No endothelial modulator (imatinib or another tyrosine kinase inhibitor targeting the same pathway as imatinib) is to be administered.
Treatment: Drugs: Imatinib
Enteral imatinib will be administered as a single 800mg loading dose (study day 1) followed by 400mg daily until study day 14 or discharge.
Other interventions: No Immune Modulator for Influenza
No immune modulating agent intended to be active against influenza is to be administered.
Treatment: Drugs: Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg. In children weighing less than 30kg, tocilizumab dose will be 12mg/kg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.
Treatment: Drugs: Baricitinib
Baricitinib will be administered at a dose that is determined by age and renal function, for up to 10 days or hospital discharge (whichever occurs first).
Other interventions: No antiviral agent for COVID-19
No antiviral agent intended to be active against SARS-CoV-2 infection is to be administered
Treatment: Drugs: Nirmatrelvir/ritonavir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days.
Treatment: Drugs: Remdesivir
Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Treatment: Drugs: Nirmatrelvir/ritonavir + remdesivir
Nirmatrelvir-ritonavir will be administered at a dose that is dependent on renal function, for five days. Remdesivir is administered at 200 mg on day one followed by 100 mg daily for a further four doses (i.e., for five doses in total) or until hospital discharge, whichever occurs first.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Intervention code [3]
0
0
Treatment: Surgery
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
All-cause mortality
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 90
Query!
Primary outcome [2]
0
0
Days alive and not receiving organ support in ICU
Query!
Assessment method [2]
0
0
Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Query!
Timepoint [2]
0
0
Day 21
Query!
Secondary outcome [1]
0
0
ICU Mortality
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Day 90
Query!
Secondary outcome [2]
0
0
ICU length of stay
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Day 90
Query!
Secondary outcome [3]
0
0
Hospital length of stay
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Day 90
Query!
Secondary outcome [4]
0
0
Ventilator free days
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Day 28
Query!
Secondary outcome [5]
0
0
Organ failure free days
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Day 28
Query!
Secondary outcome [6]
0
0
All-cause mortality
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
6 months
Query!
Secondary outcome [7]
0
0
Health-related Quality of life assessment
Query!
Assessment method [7]
0
0
EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Query!
Timepoint [7]
0
0
6 months
Query!
Secondary outcome [8]
0
0
Proportion of intubated patients who receive a tracheostomy
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Day 28
Query!
Secondary outcome [9]
0
0
Destination at time of hospital discharge
Query!
Assessment method [9]
0
0
Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Query!
Timepoint [9]
0
0
Free text Day 90
Query!
Secondary outcome [10]
0
0
Readmission to the index ICU during the index hospitalization
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Day 90
Query!
Secondary outcome [11]
0
0
World Health Organisation 8-point ordinal scale outcome
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Hospital discharge
Query!
Eligibility
Key inclusion criteria
REMAP-CAP PLATFORM INCLUSION CRITERIA:
1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission
with:
1. symptoms or signs or both that are consistent with lower respiratory tract
infection AND
2. Radiological evidence of new onset consolidation (in patients with pre-existing
radiological changes, evidence of new infiltrate)
2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
1. Non-invasive or Invasive ventilatory support;
2. Receiving infusion of vasopressor or inotropes or both
PLATFORM EXCLUSION CRITERIA:
1. Healthcare-associated pneumonia:
1. Prior to this illness, is known to have been an inpatient in any healthcare
facility within the last 30 days
2. Resident of a nursing home or long term care facility
2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
of the patient, substitute decision maker or attending physician are not committed to
full active treatment
3. Previous participation in this REMAP within the last 90 days
REMAP-COVID PLATFORM INCLUSION CRITERIA
1. Adult patients (= 18 years) admitted to hospital with acute illness due to suspected or
proven pandemic infection.
REMAP-COVID PLATFORM EXCLUSION CRITERIA
1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
of the patient, substitute decision maker or attending physician are not committed to
full active treatment
2. Patient is expected to be discharged from hospital today or tomorrow
3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute
illness due to suspected or proven pandemic infection.
4. Previous participation in this REMAP within the last 90 days
DOMAIN-SPECIFIC ELIGIBLE CRITERIA:
Each domain may have additional eligibility criteria. Refer to the study website for more
information (www.remapcap.org).
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Factorial
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/04/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/02/2028
Query!
Actual
Query!
Sample size
Target
20000
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
Canberra Hospital - Canberra
Query!
Recruitment hospital [2]
0
0
Bankstown-Lidcombe Hospital - Bankstown
Query!
Recruitment hospital [3]
0
0
Blacktown Hospital - Blacktown
Query!
Recruitment hospital [4]
0
0
Campbelltown Hospital - Campbelltown
Query!
Recruitment hospital [5]
0
0
Sutherland Hospital - Caringbah
Query!
Recruitment hospital [6]
0
0
Concord Hospital - Concord
Query!
Recruitment hospital [7]
0
0
Dubbo Base Hospital - Dubbo
Query!
Recruitment hospital [8]
0
0
Northern Beaches Hospital - Frenchs Forest
Query!
Recruitment hospital [9]
0
0
Nepean Hospital - Kingswood
Query!
Recruitment hospital [10]
0
0
St. George Hospital - Kogarah
Query!
Recruitment hospital [11]
0
0
Liverpool Hospital - Liverpool
Query!
Recruitment hospital [12]
0
0
John Hunter Hospital - Newcastle
Query!
Recruitment hospital [13]
0
0
Orange Health Service - Orange
Query!
Recruitment hospital [14]
0
0
St Vincent's Hospital Sydney - Sydney
Query!
Recruitment hospital [15]
0
0
Prince of Wales Hospital - Sydney
Query!
Recruitment hospital [16]
0
0
Royal Prince Alfred Hospital - Sydney
Query!
Recruitment hospital [17]
0
0
Royal North Shore Hospital - Sydney
Query!
Recruitment hospital [18]
0
0
Wollongong Hospital - Sydney
Query!
Recruitment hospital [19]
0
0
Wagga Wagga Base Hospital - Wagga Wagga
Query!
Recruitment hospital [20]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [21]
0
0
Royal Darwin Hospital, - Darwin
Query!
Recruitment hospital [22]
0
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment hospital [23]
0
0
The Prince Charles Hospital - Brisbane
Query!
Recruitment hospital [24]
0
0
Mater Hospital Brisbane - Brisbane
Query!
Recruitment hospital [25]
0
0
Princess Alexandra Hospital - Brisbane
Query!
Recruitment hospital [26]
0
0
Caboolture Hospital - Caboolture
Query!
Recruitment hospital [27]
0
0
Queen Elizabeth II Jubilee Hospital - Coopers Plains
Query!
Recruitment hospital [28]
0
0
Logan Hospital - Logan
Query!
Recruitment hospital [29]
0
0
Redcliffe Hospital - Redcliffe
Query!
Recruitment hospital [30]
0
0
Rockhampton Hospital - Rockhampton
Query!
Recruitment hospital [31]
0
0
Gold Coast University Hospital - Southport
Query!
Recruitment hospital [32]
0
0
Toowoomba Hospital - Toowoomba
Query!
Recruitment hospital [33]
0
0
Townsville Hospital - Townsville
Query!
Recruitment hospital [34]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [35]
0
0
The Queen Elizabeth Hospital - Adelaide
Query!
Recruitment hospital [36]
0
0
Lyell McEwin Hospital - Adelaide
Query!
Recruitment hospital [37]
0
0
Flinders Medical Centre - Bedford Park
Query!
Recruitment hospital [38]
0
0
Launceston Hospital - Launceston
Query!
Recruitment hospital [39]
0
0
Ballarat Base Hospital - Ballarat
Query!
Recruitment hospital [40]
0
0
Bendigo Hospital - Bendigo
Query!
Recruitment hospital [41]
0
0
Casey Hospital - Berwick
Query!
Recruitment hospital [42]
0
0
Box Hill Hospital - Box Hill
Query!
Recruitment hospital [43]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [44]
0
0
Dandenong Hospital - Dandenong
Query!
Recruitment hospital [45]
0
0
Angliss Hospital - Ferntree Gully
Query!
Recruitment hospital [46]
0
0
Footscray Hospital - Footscray
Query!
Recruitment hospital [47]
0
0
University Hosptial Geelong - Geelong
Query!
Recruitment hospital [48]
0
0
The Alfred Hospital - Melbourne
Query!
Recruitment hospital [49]
0
0
Royal Melbourne Hospital - Melbourne
Query!
Recruitment hospital [50]
0
0
St Vincent's Hospital Melbourne - Melbourne
Query!
Recruitment hospital [51]
0
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [52]
0
0
Sunshine Hospital - Sunshine
Query!
Recruitment hospital [53]
0
0
Werribee Mercy Hospital - Werribee
Query!
Recruitment hospital [54]
0
0
St John of God Hospital Midland - Midland
Query!
Recruitment hospital [55]
0
0
St John of God Hospital Murdoch - Murdoch
Query!
Recruitment hospital [56]
0
0
Royal Perth Hospital - Perth
Query!
Recruitment hospital [57]
0
0
Sir Charles Gairdner Hospital - Perth
Query!
Recruitment hospital [58]
0
0
Fiona Stanley Hospital - Perth
Query!
Recruitment hospital [59]
0
0
St John of God Subiaco - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2605 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
2200 - Bankstown
Query!
Recruitment postcode(s) [3]
0
0
2148 - Blacktown
Query!
Recruitment postcode(s) [4]
0
0
2560 - Campbelltown
Query!
Recruitment postcode(s) [5]
0
0
2229 - Caringbah
Query!
Recruitment postcode(s) [6]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [7]
0
0
2830 - Dubbo
Query!
Recruitment postcode(s) [8]
0
0
2086 - Frenchs Forest
Query!
Recruitment postcode(s) [9]
0
0
2750 - Kingswood
Query!
Recruitment postcode(s) [10]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [11]
0
0
2170 - Liverpool
Query!
Recruitment postcode(s) [12]
0
0
2305 - Newcastle
Query!
Recruitment postcode(s) [13]
0
0
2800 - Orange
Query!
Recruitment postcode(s) [14]
0
0
2010 - Sydney
Query!
Recruitment postcode(s) [15]
0
0
2031 - Sydney
Query!
Recruitment postcode(s) [16]
0
0
2050 - Sydney
Query!
Recruitment postcode(s) [17]
0
0
2065 - Sydney
Query!
Recruitment postcode(s) [18]
0
0
2500 - Sydney
Query!
Recruitment postcode(s) [19]
0
0
2650 - Wagga Wagga
Query!
Recruitment postcode(s) [20]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [21]
0
0
0810 - Darwin
Query!
Recruitment postcode(s) [22]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [23]
0
0
4032 - Brisbane
Query!
Recruitment postcode(s) [24]
0
0
4101 - Brisbane
Query!
Recruitment postcode(s) [25]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [26]
0
0
4510 - Caboolture
Query!
Recruitment postcode(s) [27]
0
0
4110 - Coopers Plains
Query!
Recruitment postcode(s) [28]
0
0
4129 - Logan
Query!
Recruitment postcode(s) [29]
0
0
4020 - Redcliffe
Query!
Recruitment postcode(s) [30]
0
0
4700 - Rockhampton
Query!
Recruitment postcode(s) [31]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [32]
0
0
4350 - Toowoomba
Query!
Recruitment postcode(s) [33]
0
0
4814 - Townsville
Query!
Recruitment postcode(s) [34]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [35]
0
0
5011 - Adelaide
Query!
Recruitment postcode(s) [36]
0
0
5112 - Adelaide
Query!
Recruitment postcode(s) [37]
0
0
5042 - Bedford Park
Query!
Recruitment postcode(s) [38]
0
0
7250 - Launceston
Query!
Recruitment postcode(s) [39]
0
0
3350 - Ballarat
Query!
Recruitment postcode(s) [40]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [41]
0
0
3806 - Berwick
Query!
Recruitment postcode(s) [42]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [43]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [44]
0
0
3175 - Dandenong
Query!
Recruitment postcode(s) [45]
0
0
3156 - Ferntree Gully
Query!
Recruitment postcode(s) [46]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [47]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [48]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [49]
0
0
3050 - Melbourne
Query!
Recruitment postcode(s) [50]
0
0
3065 - Melbourne
Query!
Recruitment postcode(s) [51]
0
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [52]
0
0
3021 - Sunshine
Query!
Recruitment postcode(s) [53]
0
0
3030 - Werribee
Query!
Recruitment postcode(s) [54]
0
0
6056 - Midland
Query!
Recruitment postcode(s) [55]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [56]
0
0
6000 - Perth
Query!
Recruitment postcode(s) [57]
0
0
6009 - Perth
Query!
Recruitment postcode(s) [58]
0
0
6150 - Perth
Query!
Recruitment postcode(s) [59]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Louisiana
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
North Carolina
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Ohio
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Oregon
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Pennsylvania
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Rhode Island
Query!
Country [12]
0
0
Belgium
Query!
State/province [12]
0
0
Brugge
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Charleroi
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Edegem
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Gent
Query!
Country [16]
0
0
Canada
Query!
State/province [16]
0
0
Alberta
Query!
Country [17]
0
0
Canada
Query!
State/province [17]
0
0
British Columbia
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Manitoba
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
New Brunswick
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Ontario
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Saskatchewan
Query!
Country [23]
0
0
Colombia
Query!
State/province [23]
0
0
Cundinamarca
Query!
Country [24]
0
0
Croatia
Query!
State/province [24]
0
0
Požega
Query!
Country [25]
0
0
Croatia
Query!
State/province [25]
0
0
Zagreb
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Berlin
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Cologne
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Frankfurt
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Hamburg
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Hannover
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Jena
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Leipzig
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Tübingen
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Würzburg
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Nyíregyháza
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Veszprém
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Ózd
Query!
Country [38]
0
0
India
Query!
State/province [38]
0
0
Tamil Nadu
Query!
Country [39]
0
0
Ireland
Query!
State/province [39]
0
0
Dublin
Query!
Country [40]
0
0
Ireland
Query!
State/province [40]
0
0
Galway
Query!
Country [41]
0
0
Japan
Query!
State/province [41]
0
0
Kanagawa
Query!
Country [42]
0
0
Japan
Query!
State/province [42]
0
0
Kumamoto
Query!
Country [43]
0
0
Japan
Query!
State/province [43]
0
0
Osaka
Query!
Country [44]
0
0
Japan
Query!
State/province [44]
0
0
Tokyo
Query!
Country [45]
0
0
Japan
Query!
State/province [45]
0
0
Wakayama
Query!
Country [46]
0
0
Nepal
Query!
State/province [46]
0
0
Bharatpur
Query!
Country [47]
0
0
Nepal
Query!
State/province [47]
0
0
Kathmandu
Query!
Country [48]
0
0
Netherlands
Query!
State/province [48]
0
0
Amersfoort
Query!
Country [49]
0
0
Netherlands
Query!
State/province [49]
0
0
Den Bosch
Query!
Country [50]
0
0
Netherlands
Query!
State/province [50]
0
0
Groningen
Query!
Country [51]
0
0
Netherlands
Query!
State/province [51]
0
0
Leiden
Query!
Country [52]
0
0
Netherlands
Query!
State/province [52]
0
0
Nijmegen
Query!
Country [53]
0
0
Netherlands
Query!
State/province [53]
0
0
Utrecht
Query!
Country [54]
0
0
New Zealand
Query!
State/province [54]
0
0
Auckland
Query!
Country [55]
0
0
New Zealand
Query!
State/province [55]
0
0
Christchurch
Query!
Country [56]
0
0
New Zealand
Query!
State/province [56]
0
0
Hamilton
Query!
Country [57]
0
0
New Zealand
Query!
State/province [57]
0
0
New Plymouth
Query!
Country [58]
0
0
New Zealand
Query!
State/province [58]
0
0
Rotorua
Query!
Country [59]
0
0
New Zealand
Query!
State/province [59]
0
0
Tauranga
Query!
Country [60]
0
0
New Zealand
Query!
State/province [60]
0
0
Wellington
Query!
Country [61]
0
0
New Zealand
Query!
State/province [61]
0
0
Whangarei
Query!
Country [62]
0
0
Pakistan
Query!
State/province [62]
0
0
Sindh
Query!
Country [63]
0
0
Portugal
Query!
State/province [63]
0
0
Abrantes
Query!
Country [64]
0
0
Portugal
Query!
State/province [64]
0
0
Lisboa
Query!
Country [65]
0
0
Romania
Query!
State/province [65]
0
0
Bucharest
Query!
Country [66]
0
0
Saudi Arabia
Query!
State/province [66]
0
0
Riyadh
Query!
Country [67]
0
0
Spain
Query!
State/province [67]
0
0
Barcelona
Query!
Country [68]
0
0
Spain
Query!
State/province [68]
0
0
Córdoba
Query!
Country [69]
0
0
United Kingdom
Query!
State/province [69]
0
0
England
Query!
Country [70]
0
0
United Kingdom
Query!
State/province [70]
0
0
Northern Ireland
Query!
Country [71]
0
0
United Kingdom
Query!
State/province [71]
0
0
Scotland
Query!
Country [72]
0
0
United Kingdom
Query!
State/province [72]
0
0
Wales
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
UMC Utrecht
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Australian and New Zealand Intensive Care Research Centre
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Medical Research Institute of New Zealand
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
Unity Health
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Berry Consultants
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Global Coalition for Adaptive Research
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Other
Query!
Name [6]
0
0
University of Pittsburgh Medical Center
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Other
Query!
Name [7]
0
0
Intensive Care National Audit & Research Centre
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Other collaborator category [8]
0
0
Other
Query!
Name [8]
0
0
St. Marianna University School of Medicine
Query!
Address [8]
0
0
Query!
Country [8]
0
0
Query!
Other collaborator category [9]
0
0
Other
Query!
Name [9]
0
0
National Intensive Care Surveillance MORU
Query!
Address [9]
0
0
Query!
Country [9]
0
0
Query!
Other collaborator category [10]
0
0
Other
Query!
Name [10]
0
0
National University Hospital, Singapore
Query!
Address [10]
0
0
Query!
Country [10]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for
community-acquired pneumonia.
The purpose of this study is to evaluate the effect of a range of interventions to improve
outcome of patients admitted to intensive care with community-acquired pneumonia.
In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple
treatment modalities in the event of a respiratory pandemic such as COVID-19.
REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in
the United States of America.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02735707
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Steve Webb, Prof
Query!
Address
0
0
Monash University, Study Chair REMAP-CAP Australia
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Cameron Green, MSc
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02735707
Download to PDF